GGrantIndex
← Search

Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE) Infections

$971,302N01FY2022AINIH

Dynport Vaccine Company, Llc, Frederick MD

Investigators

Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

View original record on NIH RePORTER →
Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE) Infections · GrantIndex